For the second time Celon Pharma will participate in the European Respiratory Congress (ERS), which is the meeting place for international leaders behind the most interesting scientific discoveries – this time held in Amsterdam. Last year the Congress was held in Munich and was participated by 21 958 delegates and 195 exhibitors, while Celon Pharma's stand was one of the most popular among the visitors.
This year's ERS Congress sessions and workshops will cover therapeutic areas related to the respiratory system, pneumonology as well as healthcare in disorders related to the lungs, trachea, bronchi and the diaphragm.
Everyone who on 26-30 September visits Celon Pharma's multimedia stand will get the chance to learn about the unique features of the Salmex Orbicel inhaler, user instructions and the four-step pictogram guidelines for inhalation placed on the inhaler. The benefits of using the fluticasone/salmeterol combination in an Orbicel inhaler will also be presented.
Maciej Wieczorek, CEO of Celon Pharma S.A.: Our modern, fully automated production line for Salmex, which covers the entire production process, from making plastic parts to packaging the finished product will be presented for the first time at the Congress. Salmex is our flagship product which eventually will also be available in other EU countries.
Furthermore, the Celon Pharma R&D department will also present two studies related to JAK and PI3K inhibitors at the poster session.